1. Home
  2. MOVE vs APRE Comparison

MOVE vs APRE Comparison

Compare MOVE & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MOVE

Movano Inc.

HOLD

Current Price

$22.10

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Logo Aprea Therapeutics Inc.

APRE

Aprea Therapeutics Inc.

HOLD

Current Price

$0.81

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MOVE
APRE
Founded
2018
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
11.5M
IPO Year
2021
2019

Fundamental Metrics

Financial Performance
Metric
MOVE
APRE
Price
$22.10
$0.81
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$4.10
AVG Volume (30 Days)
41.4K
102.6K
Earning Date
04-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
21.22
EPS
N/A
N/A
Revenue
$433,000.00
N/A
Revenue This Year
$1,460.71
N/A
Revenue Next Year
$96.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.52
$0.55
52 Week High
$34.87
$2.22

Technical Indicators

Market Signals
Indicator
MOVE
APRE
Relative Strength Index (RSI) 61.74 41.45
Support Level $6.27 $0.57
Resistance Level $25.90 $0.98
Average True Range (ATR) 2.09 0.07
MACD 0.10 -0.00
Stochastic Oscillator 80.00 26.01

Price Performance

Historical Comparison
MOVE
APRE

About MOVE Movano Inc.

Corvex Inc is an AI cloud computing company that provides computing infrastructure for artificial intelligence workloads, including GPU-accelerated computing, confidential computing, and inference services. Its offerings are used by government and enterprise customers, including those with regulated workloads, to support the deployment and operation of AI models and data processing systems. The company generates revenue from the sale of Wellness Rings, portable chargers and charging cables, ring sizers, and mobile applications.

About APRE Aprea Therapeutics Inc.

Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.

Share on Social Networks: